N. Yamamoto

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
N Yamamoto, N. Yamamoto, Nobuyuki Yamamoto
Publication record
749 papers · 23,812 citations · H-index 68

PAPERS

Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non–Small-Cell Lung Cancer
20237 citationsauthor #2
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
202325 citationsauthor #21
Tumor microenvironment landscape of non-small cell lung cancer reveals resistance mechanisms for PD-L1 blockade following chemoradiotherapy: a multi-center prospective biomarker study (WJOG11518L/SUBMARINE).
20239 citationsauthor #23
Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial
202314 citationsauthor #8
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
20230 citationsauthor #9
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
20231 citationsauthor #18
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407
202312 citationsauthor #4
First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities
202334 citationsauthor #13
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
20237 citationsauthor #14
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).
20238 citationsauthor #10
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
20233 citationsauthor #16
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L).
20230 citationsauthor #16
Pathological images machine learning and prediction of long-term efficacy for immunotherapy in small cell lung cancer.
20230 citationsauthor #18
First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial
202315 citationsauthor #14
Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study
202342 citationsauthor #11
Abstract 2173: A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE)
20230 citationsauthor #21
[Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
20230 citationsauthor #2
Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study
20230 citationsauthor #16
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
20236 citationsauthor #19
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
202319 citationsauthor #3
Response to "Letter to the Editor" From David Y. Mak et al.
20230 citationsauthor #4
Comprehensive genomic profiling before the first-line setting versus after the completion of standard of care in patients with previously untreated advanced solid tumors: The prospective FIRST-Dx study.
20230 citationsauthor #12
Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
20233 citationsauthor #8
P5-6 Clinical feasibility and current trends of approved multigene panels in a genomic medicine cooperative hospital
20220 citationsauthor #14
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS)
20220 citationsauthor #18
The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study
20221 citationsauthor #3
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial
202276 citationsauthor #21
MO44-4 Phase II study of nivolumab rechallenge in advanced NSCLC pts who responded to prior anti-PD-1/L1 inhibitors; WJOG 9616L
20220 citationsauthor #14
1015P Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1 negative or weakly positive advanced non-small cell lung cancer after disease progression on platinum-based therapy: WJOG10317L study (EMERALD)
20220 citationsauthor #16
Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
20220 citationsauthor #4
Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society
20223 citationsauthor #2
P68-5 Prospective trial of comprehensive genomic profiling for patients with chemotherapy-naïve cancer (FIRST-Dx trial)
20220 citationsauthor #11
Reply to Binghao Zhao et al.
20220 citationsauthor #4
Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)
20220 citationsauthor #15
Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance
20225 citationsauthor #1
The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.
20221 citationsauthor #18
O6-3 The significance of ultra-low EGFR T790M mutations on EGFR-TKI efficacy in patients with NSCLC -the WJOG13119L study
20220 citationsauthor #18
Current methods of preventing infectious disease and managing febrile neutropenia in childhood cancer patients: a nationwide survey in Japan
20224 citationsauthor #3
Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
20221 citationsauthor #11
Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment.
20221 citationsauthor #18
Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)
20222 citationsauthor #5
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
202244 citationsauthor #19
Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes
20227 citationsauthor #11
Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study
202217 citationsauthor #11
Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial.
20220 citationsauthor #9
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
20220 citationsauthor #9
Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
20228 citationsauthor #18
Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study.
202294 citationsauthor #18
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
202210 citationsauthor #15
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
20226 citationsauthor #9
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients
20227 citationsauthor #12
Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L).
202225 citationsauthor #15
NEPTUNE: Phase III Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
202255 citationsauthor #6
Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study
20227 citationsauthor #9
Impact of underrepresented populations on clinical outcomes of chemo-immunotherapy for extensive-stage small cell lung cancer: Real-world prospective cohort study.
20222 citationsauthor #19
Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study
202116 citationsauthor #13
O11-3 Phase 2 trial of atezolizumab with bevacizumab for patients with PD-L1 high non-Sq NSCLC (WJOG10718L/At Be Study)
20212 citationsauthor #15
Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance
202123 citationsauthor #1
Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing hemodialysis: A short report
20210 citationsauthor #6
Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A).
20217 citationsauthor #14
MO29-2 Osimertinib for RT-naïve CNS metastasis of EGFRm NSCLC: pll OCEAN study (LOGIK 1603/WJOG 9116L), part of T790M cohort
20210 citationsauthor #10
Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
202118 citationsauthor #17
Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations
202113 citationsauthor #16
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study
20216 citationsauthor #15
MA02.05 A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib
20212 citationsauthor #13
Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L
202159 citationsauthor #17
MO18-5 Establishment of organoids derived from patients with advanced thoracic malignancies
20210 citationsauthor #15
P33-1 Clinical feasibility of approved multigene panels in a Japanese local cancer accredited hospital
20210 citationsauthor #11
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.
202117 citationsauthor #35
MO36-4 A multi-institutional, single-arm phase II study of pembrolizumab plus amrubicin in relapsed small cell lung cancer
20212 citationsauthor #13
Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy
202115 citationsauthor #25
1333P Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study
20210 citationsauthor #17
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)
20214 citationsauthor #16
A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: Capital study.
20211 citationsauthor #17
A phase II study of osimertinib for radiotherapy-naïve CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L).
202144 citationsauthor #19
A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)
20215 citationsauthor #9
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
20219 citationsauthor #11
First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset
202111 citationsauthor #14
Efficacy and Safety of Carboplatin With Nab-Paclitaxel Versus Docetaxel in Elderly Patients with Squamous-Cell Lung Cancer (CAPITAL): A Randomized, Multicenter, Open-Label, Phase III Trial
20210 citationsauthor #22
Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.
202129 citationsauthor #12
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
202124 citationsauthor #21
Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)
20214 citationsauthor #16
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
202120 citationsauthor #14
Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial
20213 citationsauthor #5
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
202121 citationsauthor #10
Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).
20219 citationsauthor #18
Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.
202184 citationsauthor #18
A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
202154 citationsauthor #19
Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation
20214 citationsauthor #12
Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency department
20216 citationsauthor #10
1291P A phase II study of nivolumab rechallenge therapy in advanced NSCLC patients who responded to prior anti-PD-1/L1 inhibitors: West Japan Oncology Group 9616L
20213 citationsauthor #14
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
202144 citationsauthor #21
A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).
20212 citationsauthor #19
MO37-6 Longitudinal disease monitoring with ctDNA during osimertinib treatment in EGFR T790M positive NSCLC patients (WJOG8815L)
20210 citationsauthor #13
Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
20214 citationsauthor #11
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
2021138 citationsauthor #17
Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors
202120 citationsauthor #14
Retraction
20210 citationsauthor #14
MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L
20211 citationsauthor #17
MO25-4 Safety and efficacy of the combination of platinum, pemetrexed, and pembrolizumab in chemo-naive patients with NSCLC
20210 citationsauthor #19

TIMELINE

1985 0 citations

1986 0 citations

1993 0 citations

1994 16 citations

1995 95 citations

1996 97 citations

1998 0 citations

2000 41 citations

2001 89 citations

2002 39 citations

2003 295 citations

2004 117 citations

2005 21 citations

2006 640 citations

2007 164 citations

2008 980 citations

2009 269 citations

2010 1,507 citations

2011 964 citations

2012 1,444 citations

2013 5,185 citations

2014 1,754 citations

2015 3,230 citations

2016 1,183 citations

2017 1,748 citations

2018 887 citations

2019 961 citations

2020 611 citations

2021 845 citations

2022 376 citations

2023 205 citations

Unknown 64 citations

N. Yamamoto

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT